{"id":847261,"date":"2025-05-06T09:13:01","date_gmt":"2025-05-06T13:13:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\/"},"modified":"2025-05-06T09:13:01","modified_gmt":"2025-05-06T13:13:01","slug":"allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\/","title":{"rendered":"Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT\/5:00 p.m. ET<\/li>\n<\/ul>\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., May  06, 2025  (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc.\u00a0(Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T\u2122) products for cancer and autoimmune disease, today announced\u00a0that it will report the first quarter 2025 financial results and provide a business update on May 13, 2025, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT\/5:00 p.m. ET.<\/p>\n<p>\n        <strong>Listen-Only Webcast<\/strong><br \/>\n        <br \/>The listen-only webcast will be made available on the Company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8ifVeCqHPeuFFPsB-CxDUIGFCujDuSc-3mwTGbnxrAF3oBkkTeK7yYG0x_2g-PtWCfFrrbxE1keJUBzxrg1JAhaPmk4XZgiXaFs749WPlG4=\" rel=\"nofollow\" target=\"_blank\">www.allogene.com<\/a> under the Investors tab in the News and Events section. A replay will be available on the Company&#8217;s website for approximately 30 days.<\/p>\n<p>\n        <strong>Conference Call Registration<\/strong><br \/>\n        <br \/>If you would like the option to ask a question on the conference call, please use\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=opq4A-h0ovFc8czoRgGbtN_wMgCjsDC0F9911X7yMVj1vDq6BIp2giB5w1r5LgREkYpPGA0BfuM3ayUURfNWdE8l4XhyQQ0FLHsYk8DhMSJFElCCMQStwnZKKcuM6hbgFbpY0pwuXMrznx5l2-a0kYH9Op0kfNE3rAuawoZABb0=\" rel=\"nofollow\" target=\"_blank\">this link\u00a0<\/a>to register. Upon registering for the conference call, you will receive a personal PIN to access the call.<\/p>\n<p>\n        <strong>About Allogene Therapeutics<\/strong><br \/>\n        <br \/>Allogene Therapeutics, with headquarters in\u00a0South San Francisco, is a clinical-stage\u00a0biotechnology company pioneering the development of allogeneic chimeric antigen receptor T\u00a0cell (AlloCAR T<sup>\u2122<\/sup>) products for cancer and autoimmune disease. Led by a management team with significant\u00a0experience in cell therapy, Allogene is developing a pipeline of \u201coff-the-shelf\u201d CAR T cell product\u00a0candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at\u00a0greater scale to more patients. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8ifVeCqHPeuFFPsB-CxDUBZif5qhOdPhw20TVpH5trwr49ABveYYbscgPit2YCDusAjtxRnRT3uGS9zFOCzu3Az9urFWhAmw4sFVciCiRir5MQxu1gc9DQyZ3KQ_eizd8D-GZOw60ht_mOPsP625DeiKTeWSdoqVY7nx1cMw_AoY-UAo5s2ehiYycLzlTJMwteuGvoO1EE0vZVMhN2et5yAu5qcZEpvj2Xo-nR6RAMY=\" rel=\"nofollow\" target=\"_blank\">www.allogene.com<\/a>, and follow\u00a0Allogene Therapeutics\u00a0on X and LinkedIn.<\/p>\n<p>\n        <strong>Cautionary Note on Forward-Looking Statements for Allogene<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene\u2019s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene\u2019s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene\u2019s filings with the\u00a0SEC, including without limitation under the \u201cRisk Factors\u201d heading in its Form 10-K filed for the year ended\u00a0December 31, 2024. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n<p>AlloCAR T\u2122 is a trademark of\u00a0Allogene Therapeutics, Inc.<\/p>\n<p>\n        <strong>Allogene Media\/Investor Contact:<\/strong><br \/>\n        <br \/>Christine Cassiano<br \/>EVP, Chief Corporate Affairs &amp; Brand Strategy Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dfp4042izvnCZrX1aYvjc88AXMxhTS7rgZDY2s4_pv8L20oDdW0P4M3eTYoEAo8_SAfBLPqAqUdo_U3ixiJGgZ4n7fs3GFd-7oEfiA_rGoawE_fLB_-jFaolMzLsjIy3\" rel=\"nofollow\" target=\"_blank\">Christine.Cassiano@allogene.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NTE0OCM2OTIyMzUwIzIxMjQyNDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MTI3OWQ0M2QtODgyNy00NTk3LThmMmEtMGViN2VkMmM4NGNhLTExMzU4MTgtMjAyNS0wNS0wNi1lbg==\/tiny\/Allogene-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT\/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc.\u00a0(Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T\u2122) products for cancer and autoimmune disease, today announced\u00a0that it will report the first quarter 2025 financial results and provide a business update on May 13, 2025, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT\/5:00 p.m. ET. Listen-Only Webcast The listen-only webcast will be made available on the Company&#8217;s website at www.allogene.com under the Investors tab in the News and Events section. A replay &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-847261","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT\/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc.\u00a0(Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T\u2122) products for cancer and autoimmune disease, today announced\u00a0that it will report the first quarter 2025 financial results and provide a business update on May 13, 2025, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT\/5:00 p.m. ET. Listen-Only Webcast The listen-only webcast will be made available on the Company&#8217;s website at www.allogene.com under the Investors tab in the News and Events section. A replay &hellip; Continue reading &quot;Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-06T13:13:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NTE0OCM2OTIyMzUwIzIxMjQyNDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update\",\"datePublished\":\"2025-05-06T13:13:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\\\/\"},\"wordCount\":519,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NTE0OCM2OTIyMzUwIzIxMjQyNDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\\\/\",\"name\":\"Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NTE0OCM2OTIyMzUwIzIxMjQyNDc=\",\"datePublished\":\"2025-05-06T13:13:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NTE0OCM2OTIyMzUwIzIxMjQyNDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NTE0OCM2OTIyMzUwIzIxMjQyNDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\/","og_locale":"en_US","og_type":"article","og_title":"Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update - Market Newsdesk","og_description":"Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT\/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc.\u00a0(Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T\u2122) products for cancer and autoimmune disease, today announced\u00a0that it will report the first quarter 2025 financial results and provide a business update on May 13, 2025, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT\/5:00 p.m. ET. Listen-Only Webcast The listen-only webcast will be made available on the Company&#8217;s website at www.allogene.com under the Investors tab in the News and Events section. A replay &hellip; Continue reading \"Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-06T13:13:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NTE0OCM2OTIyMzUwIzIxMjQyNDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update","datePublished":"2025-05-06T13:13:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\/"},"wordCount":519,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NTE0OCM2OTIyMzUwIzIxMjQyNDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\/","name":"Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NTE0OCM2OTIyMzUwIzIxMjQyNDc=","datePublished":"2025-05-06T13:13:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NTE0OCM2OTIyMzUwIzIxMjQyNDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NTE0OCM2OTIyMzUwIzIxMjQyNDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/847261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=847261"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/847261\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=847261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=847261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=847261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}